Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive
medications have increased risk for severe COVID-19. Although mRNA-based SARS-…

Background: Individuals with chronic inflammatory diseases (CID) are frequently treated
with immunosuppressive medications that can increase their risk of severe COVID-19. While …

Objective Little is known regarding the reactogenicity and related SARS–CoV‐2 vaccine
response in patients with chronic inflammatory disease (CID). Our objective was to characterize …

Objective Immunocompromised patients with chronic inflammatory disease (CID) may have
experienced additional psychosocial burden during the COVID‐19 pandemic due to their …

Objective Immunocompromised patients with chronic inflammatory diseases (CID) may have
experienced additional psychosocial burden during the COVID‐19 pandemic due to an …

Background: Waning levels of anti-SARS-CoV-2 Spike (S) antibodies, particularly neutralizing,
are associated with the risk of breakthrough infections. The impact of immunosuppression …

Abstracts Page 1 in adults. Biological therapy with anti-CD20 (rituximab) is an option in
patient that does not respond to conventional therapy. Methods The aim of this study is to …

Background The gold standard for diagnosing lupus nephritis is the renal biopsy. While it
has several significant benefits, this procedure is not without risk (ie bleeding) and only …

Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and
Chronic Inflammatory Diseases | Arthritis & Rheumatology; 73:3316-3318, 2021. | Web of …

Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with
Autoimmune and Inflammatory Disease | Arthritis & Rheumatology; 73:220-223, 2021. | Web of …